Significant Contract Modifications ($10M+) — June 23, 2026

Analogic Corp secured a $138.3 million firm-fixed-price delivery order from TSA for full-sized CT systems, with a total potential value of $499.7 million through 2033. The competitive win under full-and-open competition signals a strong competitive moat in the airport security detection market.

START2 GROUP, INC. won a $141.3 million firm-fixed-price BARDA contract for biotechnology R&D, but only $2.8 million has been outlayed, indicating early-stage funding and milestone-based payments. The company is a small, foreign-owned, self-certified small disadvantaged business, raising scalability and investor confidence concerns.

Leidos Biomedical Research's $121.5 million cost-plus-fixed-fee NIH contract for NIAID VRC research ends in August 2024, with only $4.3 million in remaining options. The re-compete or follow-on award will be a key catalyst for Leidos Holdings' health R&D revenue stream.

START2 GROUP, INC.'s $141.3 million BARDA contract has only $2.8 million outlayed, indicating high execution risk due to milestone-based payments and the company's small business status.

Analogic Corp's $138.3 million TSA contract represents a significant revenue concentration for the company, with a potential total value of $499.7 million over 11 years. Any budget cuts or technology shifts at TSA could materially impact Analogic's revenue.

Leidos Biomedical Research's $121.5 million NIH contract expires in August 2024, creating re-compete risk. NIH budget allocations for NIAID VRC research could shift, affecting the follow-on contract value.

Analogic Corp's $138.3 million TSA CT system award positions the company for long-term growth as TSA continues to deploy advanced screening technology. The $499.7 million potential value includes option exercises that could drive further revenue.

START2 GROUP, INC.'s $141.3 million BARDA contract for biotechnology R&D aligns with sustained HHS biodefense funding priorities. Successful execution could lead to follow-on awards and revenue growth for the small business.

Leidos Holdings' $121.5 million NIH contract demonstrates competitive strength in health R&D. A successful re-compete or expansion of NIAID VRC work could provide a stable revenue base and cross-selling opportunities into DoD health programs.

Both the TSA CT system award to Analogic Corp ($138.3M) and the BARDA biotechnology R&D contract to START2 GROUP ($141.3M) reflect sustained civilian agency investment in advanced technology, despite budget uncertainty. This theme supports companies providing specialized detection and biodefense solutions.

Two of three contracts ($262.8M total) are from HHS agencies (NIH and BARDA), highlighting the resilience of federal health R&D spending. Leidos Biomedical Research's $121.5M NIH contract and START2 GROUP's $141.3M BARDA contract demonstrate sustained demand for biotechnology and health research services.

{"entity"=>"Analogic Corp", "reason"=>"Won $138.3M TSA CT system delivery order with $499.7M potential value; long-term revenue visibility through 2033.", "trigger"=>"Option exercise announcements and TSA budget updates"}

{"entity"=>"START2 GROUP, INC.", "reason"=>"Awarded $141.3M BARDA contract but only $2.8M outlayed; execution risk is high.", "trigger"=>"Quarterly outlayed amount increases and milestone achievements"}

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"$121.5M NIH contract expires August 2024; re-compete outcome is a key catalyst.", "trigger"=>"Re-compete solicitation release and award decision"}